Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease

J. S. Bryson, C. D. Jennings, D. M. Lowery, S. L. Carlson, D. L. Pflugh, Be Caywood, A. M. Kaplan

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Cyclosporin A (CsA) has been used clinically to induce graft-versus-host disease following autologous bone marrow transplantation in an attempt to destroy residual leukemia cells and reduce relapse. To analyze the antitumor potential of murine syngeneic graft-versus-host disease (SGVHD), C3H/HeN mice were lethally irradiated, reconstituted with T cell-depleted syngeneic bone marrow (ATBM) and treated with CsA for 21 days. Graft-versus-leukemia activity was assessed by challenging groups of olive oil-treated control ATBM (OO-ATBM) and CsA-treated (CsA-ATBM) mice 1 week after CsA therapy with graded doses of the syngeneic 38C13 B cell lymphoma. Following CsA treatment, up to 70% of CsA-ATBM developed SGVHD and more than 70% of the animals injected with 500 38C13 cells exhibited long-term survival (MST > 80 days). In contrast, none of the OO-ATBM control mice developed SGVHD, and more than 75% of these mice died following injection of 500 38C13 tumor cells (MST = 34 days). Long-term survivors were not resistant to tumor challenge suggesting that tumor-specific immunity did not develop. Finally, class II negative 38C13 cells cultured in IL-4 or IL-10 were not inducible for MHC class II molecules, demonstrating that class II-independent antitumor mechanisms exist in SGVHD mice.

Original languageEnglish
Pages (from-to)363-372
Number of pages10
JournalBone Marrow Transplantation
Volume23
Issue number4
DOIs
StatePublished - 1999

Bibliographical note

Funding Information:
This work was supported in part by a Research Scholar Grant from the Council for Tobacco Research-USA, Inc (JSB) and Grant AI31998 from the National Institutes of Health (JSB).

Keywords

  • Cyclosporin A
  • Graft-versus-host disease
  • Graft-versus-tumor
  • Syngeneic bone marrow transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Rejection of an MHC class II negative tumor following induction of murine syngeneic graft-versus-host disease'. Together they form a unique fingerprint.

Cite this